Interrupted Etanercept Therapy: A New Case Report

Psoriasis is a chronic, immune-mediated,\r\ninflammatory disease with a high prevalence in the general population (2%). The\r\nanti-tumor necrosis factor receptor etanercept is Food and Drug Administration\r\n(FDA) approved for the treatment of moderate-to-severe plaque psoriasis. Both\r\ncontinuous and interrupted etanercept therapy is effective and well-tolerated.\r\nThis report aims to document a new case presentation of psoriasis on\r\nintermittent etanercept injection throughout 36 weeks with long-lasting\r\nsustained efficacy and no risk factor. Case Report: A 39-year-old adult male\r\npatient with long-standing chronic plaque psoriasis for 15 years duration\r\nwithout joint involvement started loading dose treatment of etanercept\r\ninjection in whom due to his work circumstances not taken maintenance therapy\r\nand showed-up at the clinic after 36 weeks from first induction therapy when\r\npartial relapse of psoriatic lesions appear in last week with continued\r\nimprovement when reintroducing loading treatment on followed-up over the next\r\n36 weeks. Conclusion: Intermittent etanercept therapy considers effective for\r\n36 weeks with prolonging sustained efficacy and without adverse effect.